McDonald's Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? McDonald's Corp trades at $273.95 (market cap $194.00B), while Vertex Pharmaceuticals Incorporated trades at $528 (market cap $134.25B). The key difference: McDonald's Corp is the larger of the two by market cap, and McDonald's Corp pays a 2.71% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MCD | VRTX | |
|---|---|---|
Market Cap | $194.00B | $134.25B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $529.65 |
52-Week Low | $262.80 | $376.62 |
Enterprise Value | $247.77B | $128.37B |
Dividend Yield | 2.71% | — |
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.
The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →